Ofatumumab

證據等級: L5

預測適應症: 8 個

Ofatumumab: From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Pregerminal Center CLL/SLL

One-Sentence Summary

Ofatumumab is a fully human anti-CD20 monoclonal antibody originally approved (as Arzerra) for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The TxGNN model's top-ranked prediction points to pregerminal center CLL/SLL — a specific IGHV-unmutated molecular subtype of the same disease — with a prediction score of 99.77%, but currently 0 clinical trials and 0 publications directly support this subtype-specific extrapolation.

Quick Overview

Item	Content
Original Indication	Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) — the drug's original core indication (as Arzerra); no formal Finland license text is available in current data
Predicted New Indication	Pregerminal center CLL/SLL (IGHV-unmutated molecular subtype)
TxGNN Prediction Score	99.77%
Evidence Level	L4
Finland Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold (Research Question stage)

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, ofatumumab is a fully human IgG1κ monoclonal antibody targeting CD20, in the same drug class as rituximab and obinutuzumab. Its efficacy in chronic lymphocytic leukemia/small lymphocytic lymphoma has been proven and forms its original approved indication.

"Pregerminal center CLL/SLL" is not a distinct disease but a molecular subtype of CLL/SLL, characterized by an unmutated IGHV gene status (pre-germinal center origin), which is typically associated with a more aggressive clinical course. Tumor cells in this subtype continue to express CD20, so ofatumumab's core cytotoxic mechanism — complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20+ B cells — remains mechanistically applicable.

However, this prediction is an indirect extrapolation from the drug's main CLL/SLL evidence base rather than a subtype-specific finding: no clinical trial or publication in this evidence pack specifically enrolled or analyzed IGHV-unmutated/pre-germinal center CLL/SLL patients as a defined subgroup for ofatumumab treatment.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Cytotoxicity

Ofatumumab is an antineoplastic biologic (anti-CD20 monoclonal antibody used in CD20+ B-cell malignancies including CLL/SLL and follicular lymphoma), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted immunotherapy (anti-CD20 monoclonal antibody), not conventional cytotoxic chemotherapy
Myelosuppression Risk	Please refer to the package insert warnings and precautions. Literature (PMID 26566719) describes a "favorable toxicity profile" in CLL patients, but no quantified hematologic toxicity data is available in the current dataset
Emetogenicity Classification	Low (monoclonal antibodies are generally minimally emetogenic; infusion-related reactions are the more prominent acute toxicity for this class)
Monitoring Items	CBC with differential, infusion-related reaction monitoring, hepatitis B screening (class recommendation for anti-CD20 agents), immunoglobulin levels
Handling Protection	Standard biologic infusion handling precautions; not subject to cytotoxic chemotherapy handling regulations, as it is a monoclonal antibody rather than a cytotoxic small molecule

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score for this specific molecular subtype is high, but it is supported by zero direct clinical trials or publications — the mechanistic rationale is entirely extrapolated from ofatumumab's broader CLL/SLL evidence base rather than subtype-specific data. This does not meet the bar to advance beyond S1 (Research Question).

To proceed, the following is needed:

Subtype-specific clinical trial or literature evidence for IGHV-unmutated/pre-germinal center CLL/SLL
TFDA/Fimea package insert warnings and contraindications (currently a Blocking data gap, DG001) — required before any S1 safety screening
Confirmed mechanism-of-action data from DrugBank (High-severity data gap, DG002)
Finland regulatory/market status update, given the drug is currently not marketed there

Note for context: within this same evidence pack, other TxGNN-predicted indications for ofatumumab carry substantially stronger evidence — chronic lymphocytic leukemia/small lymphocytic lymphoma overall (rank 5, L1, "Proceed with Guardrails," including completed Phase 3 trials) and follicular lymphoma (rank 3, L2, multiple completed Phase 2/3 trials). Those candidates may warrant separate, higher-priority evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.